| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 23.96% | Needham | $140 → $119 | Maintains | Buy |
| 07/27/2023 | 51.04% | JP Morgan | $125 → $145 | Maintains | Overweight |
| 07/27/2023 | 45.83% | Needham | $139 → $140 | Maintains | Buy |
| 07/27/2023 | 46.88% | Keybanc | $131 → $141 | Maintains | Overweight |
| 07/24/2023 | 44.79% | Needham | → $139 | Reiterates | Buy → Buy |
| 06/05/2023 | 44.79% | Needham | $135 → $139 | Maintains | Buy |
| 05/22/2023 | 45.83% | CL King | → $140 | Initiates Coverage On | → Buy |
| 04/27/2023 | 35.42% | Stifel | $118 → $130 | Maintains | Buy |
| 04/27/2023 | 33.33% | Piper Sandler | $118 → $128 | Maintains | Overweight |
| 04/27/2023 | 23.96% | Wells Fargo | $96 → $119 | Maintains | Equal-Weight |
| 04/27/2023 | 40.63% | Needham | $122 → $135 | Maintains | Buy |
| 04/27/2023 | 36.46% | Keybanc | $124 → $131 | Maintains | Overweight |
| 03/27/2023 | 29.17% | Keybanc | → $124 | Upgrades | Sector Weight → Overweight |
| 02/03/2023 | 22.92% | Piper Sandler | $108 → $118 | Maintains | Overweight |
| 02/03/2023 | 27.08% | Needham | $106 → $122 | Maintains | Buy |
| 11/15/2022 | 10.42% | Needham | $90 → $106 | Maintains | Buy |
| 10/14/2022 | -6.25% | Needham | $123 → $90 | Maintains | Buy |
| 10/12/2022 | -11.46% | Jefferies | → $85 | Initiates Coverage On | → Hold |
| 08/02/2022 | 28.13% | Needham | $127 → $123 | Maintains | Buy |
| 07/28/2022 | 22.92% | Piper Sandler | $160 → $118 | Maintains | Overweight |
| 07/28/2022 | 32.29% | Needham | $155 → $127 | Maintains | Buy |
| 06/23/2022 | 14.58% | Stifel | $160 → $110 | Maintains | Buy |
| 05/05/2022 | 61.46% | Needham | $150 → $155 | Maintains | Buy |
| 01/21/2022 | 56.25% | Needham | $158 → $150 | Maintains | Buy |
| 10/28/2021 | 64.58% | Needham | $150 → $158 | Maintains | Buy |
| 10/06/2021 | 56.25% | Needham | → $150 | Upgrades | Hold → Buy |
| 07/15/2021 | 66.67% | UBS | → $160 | Initiates Coverage On | → Buy |
| 05/25/2021 | 82.29% | Barclays | → $175 | Initiates Coverage On | → Overweight |
| 04/29/2021 | 66.67% | Piper Sandler | $145 → $160 | Maintains | Overweight |
| 07/30/2020 | -1.04% | Piper Sandler | $90 → $95 | Maintains | Overweight |
| 07/30/2020 | 4.17% | Stifel | $82 → $100 | Maintains | Buy |
| 07/30/2020 | -4.17% | SVB Leerink | $82 → $92 | Maintains | Market Perform |
| 04/30/2020 | -14.58% | Stifel | $65 → $82 | Maintains | Buy |
| 04/23/2020 | -20.83% | JP Morgan | $136 → $76 | Maintains | Overweight |
| 11/26/2019 | — | Needham | Downgrades | Buy → Hold | |
| 11/12/2019 | 41.67% | JP Morgan | → $136 | Initiates Coverage On | → Overweight |
| 10/31/2019 | 22.92% | Stifel | $99 → $118 | Maintains | Buy |
| 08/22/2019 | 14.58% | Piper Sandler | $88 → $110 | Upgrades | Neutral → Overweight |
| 08/01/2019 | 3.13% | Stifel | $97 → $99 | Maintains | Buy |
| 04/18/2019 | -1.04% | Stifel | → $95 | Initiates Coverage On | → Buy |
| 04/15/2019 | -4.17% | Barclays | $85 → $92 | Maintains | Overweight |
| 02/19/2019 | -11.46% | Barclays | → $85 | Reinstates | → Overweight |
What is the target price for Conmed (CNMD)?
The latest price target for Conmed (NYSE: CNMD) was reported by Needham on October 26, 2023. The analyst firm set a price target for $119.00 expecting CNMD to rise to within 12 months (a possible 23.96% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Conmed (CNMD)?
The latest analyst rating for Conmed (NYSE: CNMD) was provided by Needham, and Conmed maintained their buy rating.
When is the next analyst rating going to be posted or updated for Conmed (CNMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating Conmed (CNMD) correct?
While ratings are subjective and will change, the latest Conmed (CNMD) rating was a maintained with a price target of $140.00 to $119.00. The current price Conmed (CNMD) is trading at is $96.00, which is out of the analyst's predicted range.